Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 15

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 15
---
 participation certificates, or the PPCs, convertible into Common Shares, and (ii) 75,000 Common Shares. Corporate Information Our registered office and principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland. Our telephone number in Switzerland is +41.44.512.2150. Our website address is https://nlspharma.com. The information contained on, or that can be accessed through, our website is not part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. The SEC also maintains an Internet website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC’s website at http://www.sec.gov.

<div align='center'>6</div>

KADIMASTEM BUSINESS Kadimastem is a clinical-stage pharmaceutical company focused on developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells, or hESCs, into functional cells. Kadimastem’s vision is to:

| ● | Replace, restore and repair the functionality of diseased and malfunctioning cells in various degenerative diseases by transplantation of healthy and functional cells; and |

| ● | Commercialize its proprietary cell lines optimized for both the cure of diabetes and the treatment of Amyotrophic Lateral Sclerosis, or ALS, and other neurodegenerative diseases, or NDDs. |

Kadimastem is primarily developing two products:

| 1. | AstroRx®, Kadimastem’s lead product, which is                                                                                     
 an off-the-shelf cryopreserved cell therapy product in clinical development for the treatment for ALS and in pre-clinical studies 
 for other neurodegenerative indications. AstroRx® is comprised of fully differentiated astrocytes, which are mainly cells that    
 support the central nervous system, or CNS.                                                                                       |

| 2. | IsletRx is Kadimastem’s treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with Type 1 diabetes and possibly Type 2 insulin dependent diabetes. |

Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute